Loading
companiesCompany
Guardant Health
Liquid biopsy leader: Guardant360 for genotyping, Reveal for MRD, Shield for screening.
Also called: Guardant
Overview
Guardant Health, based in Palo Alto and listed as GH, is the liquid biopsy leader, with Guardant360 for tumour genotyping, Reveal for measurable residual disease and Shield for screening. Guardant360 CDx is a companion diagnostic for elacestrant and other drugs, Guardant Reveal is a tumour-naive MRD test, and Shield is FDA-approved for colorectal cancer screening on the ECLIPSE trial, with a multi-cancer extension in development. OnCo links it to colorectal cancer, to comprehensive genomic profiling, ctDNA monitoring, MRD testing and multi-cancer early detection, to bottlenecks on late diagnosis, heterogeneity and residual disease, and to ideas such as an annual blinded shoot-out for liquid biopsy tests and certified reference samples. Whether a blood test can match established screening methods is the open question for Shield. Shield has its own page.
Headquarters
Palo Alto, CA, US
Scorecard
All companies#117of 1244 companies, score 46
- approved products +12
- targets +14
- modalities +2
- regions +1
- 24-month regulatory events +2
- registry trials +15
2 approved, 0 in phase 3, 0 earlier, 7 targets, 53 registry studies. Formula on the scorecards page.
Type
Diagnostics · GH
Stage
Public
Website
ApprovedBlood-based colorectal cancer screening test
The first FDA-approved blood test for colorectal cancer screening (2024), now optionally reporting other cancers too.
EstablishedTumour-naive ctDNA minimal residual disease test (methylation and genomic)
Guardant Reveal · Guardant Reveal
A blood test for leftover cancer after surgery that needs no tumour sample, so results come faster than tumour-informed tests.
ApprovedLiquid biopsy companion diagnostic test (NGS, cfDNA)
Guardant360 CDx · Guardant360 CDx
A blood test that reads a tumour's mutations without a tissue biopsy and is the FDA-approved gateway to several targeted drugs.
Similar pages
- CompanyNatera
Shares An annual blinded shoot-out for liquid biopsy tests, Certified reference samples to benchmark every tumour-DNA blood test, Kill combination arms early using circulating tumour DNA, before waiting for scans, Reference materials and open proficiency testing for residual disease tests.
- CompanyFoundation Medicine (Roche)
Shares One open atlas of how tumours escape every drug, Drop mandatory fresh biopsies where blood or archival tissue would do, Label every targetable mutation as truncal or branch on the report, Every tumour sequencing report lists open, nearby, matched trials pulled live.
- TermVariant allele frequency (VAF)
Shares Label every targetable mutation as truncal or branch on the report, An annual blinded shoot-out for liquid biopsy tests, Certified reference samples to benchmark every tumour-DNA blood test, Reference materials and open proficiency testing for residual disease tests.
- CompanyFreenome
Shares Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy, Shield, Multi-cancer early detection (MCED), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
- Key paperGALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold
Shares Continuous and near-continuous ctDNA monitoring, Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Dormant cells and minimal residual disease.
- CompanyTempus AI
Shares Label every targetable mutation as truncal or branch on the report, Every tumour sequencing report lists open, nearby, matched trials pulled live, Every tumour genomic report machine-readable and deposited nationally, Weak real-world evidence and registries.
- CompanyForesight Diagnostics
Shares Reference materials and open proficiency testing for residual disease tests, Continuous and near-continuous ctDNA monitoring, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- TechnologycfDNA fragmentomics
Shares Continuous and near-continuous ctDNA monitoring, Multi-cancer early detection (MCED), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, The hardest cancers are found late.
cancers
fronts
technologies
drugs
EstablishedTumour-naive ctDNA minimal residual disease test (methylation and genomic)
Guardant Reveal · Guardant Reveal
ApprovedLiquid biopsy companion diagnostic test (NGS, cfDNA)
Guardant360 CDx · Guardant360 CDx
ApprovedBlood-based colorectal cancer screening test
companies
trials
roadmaps
ideas
An annual blinded shoot-out for liquid biopsy testsCertified reference samples to benchmark every tumour-DNA blood testDrop mandatory fresh biopsies where blood or archival tissue would doEvery tumour genomic report machine-readable and deposited nationallyEvery tumour sequencing report lists open, nearby, matched trials pulled liveKill combination arms early using circulating tumour DNA, before waiting for scansLabel every targetable mutation as truncal or branch on the reportOffer the blood test for bowel cancer only to people who refuse stool tests or colonoscopyOne open atlas of how tumours escape every drugReference materials and open proficiency testing for residual disease testsTake ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helpsUse tumour DNA in blood to decide when to pause treatment in metastatic cancer
bottlenecks
key papers
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A blood-based genomic profiling test with the reporting and companion-diagnostic claims that let a result choose a drug without a tissue biopsy.